Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.